Scholars Central

Conference abstractPublished 24 Jan 2020

Plant-based strategies aimed at expressing a synthetic human adenosine deaminase at high levels

Authors: David Bringloe

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

An inherited disorder, ADA deficiency is a form of severe combined immunodeficiency, which is ultimately caused by an absence of adenosine deaminase (ADA), a key enzyme of the purine salvage pathway. The absence of ADA-activity in sufferers eventually results in a dysfunctional immune system due to the build-up of toxic metabolites. To date, this has been treated with mixed success, using PEG-ADA, made from purified bovine ADA coupled to polyethylene glycol. It is likely however, that an enzyme replacement therapy protocol based on recombinant human ADA would be a more effective treatment for this disease. Therefore, as a preliminary step to produce biologically active, synthetic human ADA in transgenic tobacco plants and tobacco BY-2 cell suspensions a human ADA cDNA has been inserted into a plant expression vector under the control of the CaMV 35S promoter and terminator. In an attempt to maximise the yield various recombined gene constructs containing compartmental targeting sequences were tested along with different translational regulatory sequences, such as TMV omega and RUBISCO untranslated regions. Tobacco plants and BY-2 cells transformed with cytosolic constructs showed levels of recombinant ADA of up to 97 ng mg-1 TSP. By comparison, transgenic calli expressing constructs containing apoplast-directing signals showed higher levels of recombinant ADA expression of up to 140 ng mg-1 TSP. The most significant ADA activities, however, were measured in the media of transgenic BY-2 cell suspensions prepared from transformed calli: where incorporation of a signal for arabinogalactan addition to ADA, led to a recombinant protein yield of approximately 16 mg L-1. A 336-fold increase over ADA produced by cell suspensions transformed with a cytosolic construct.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

More from this journal

The newest in Journal of Pharmacology and Medicinal Chemistry.

All its articles

Conferences in this field

Upcoming conferences in this field.

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalJournal of Pharmacology and Medicinal Chemistry
  • SubjectPharmaceutical Sciences
  • BylineArticles whose byline prints “David Bringloe”